ABCL
Price
$2.04
Change
-$0.13 (-5.99%)
Updated
Apr 10, 02:06 PM (EDT)
Capitalization
643.65M
28 days until earnings call
CYBN
Price
$5.42
Change
+$0.42 (+8.40%)
Updated
Apr 9 closing price
Capitalization
102.62M
Ad is loading...

ABCL vs CYBN

Header iconABCL vs CYBN Comparison
Open Charts ABCL vs CYBNBanner chart's image
AbCellera Biologics
Price$2.04
Change-$0.13 (-5.99%)
Volume$4.76K
Capitalization643.65M
Cybin
Price$5.42
Change+$0.42 (+8.40%)
Volume$225.48K
Capitalization102.62M
ABCL vs CYBN Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. CYBN commentary
Apr 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and CYBN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 10, 2025
Stock price -- (ABCL: $2.16 vs. CYBN: $5.42)
Brand notoriety: ABCL and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 127% vs. CYBN: 77%
Market capitalization -- ABCL: $643.65M vs. CYBN: $102.62M
ABCL [@Biotechnology] is valued at $643.65M. CYBN’s [@Biotechnology] market capitalization is $102.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, ABCL is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 4 TA indicator(s) are bullish while CYBN’s TA Score has 4 bullish TA indicator(s).

  • ABCL’s TA Score: 4 bullish, 5 bearish.
  • CYBN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -2.70% price change this week, while CYBN (@Biotechnology) price change was -13.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.44%. For the same industry, the average monthly price growth was -17.96%, and the average quarterly price growth was -19.62%.

Reported Earning Dates

ABCL is expected to report earnings on Aug 12, 2025.

CYBN is expected to report earnings on Nov 13, 2024.

Industries' Descriptions

@Biotechnology (-7.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($644M) has a higher market cap than CYBN($103M). ABCL YTD gains are higher at: -26.280 vs. CYBN (-38.549). CYBN has higher annual earnings (EBITDA): -134.52M vs. ABCL (-204.15M). ABCL has more cash in the bank: 626M vs. CYBN (136M). CYBN has less debt than ABCL: CYBN (0) vs ABCL (65.4M). ABCL has higher revenues than CYBN: ABCL (28.8M) vs CYBN (0).
ABCLCYBNABCL / CYBN
Capitalization644M103M625%
EBITDA-204.15M-134.52M152%
Gain YTD-26.280-38.54968%
P/E RatioN/AN/A-
Revenue28.8M0-
Total Cash626M136M460%
Total Debt65.4M0-
TECHNICAL ANALYSIS
Technical Analysis
ABCLCYBN
RSI
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 18 days ago
77%
Bullish Trend 25 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIRDX7.260.06
+0.79%
iShares Developed Real Estate Idx Instl
PCIEX15.70N/A
N/A
PACE International Equity P
DFIVX20.18N/A
N/A
DFA International Value I
ALARX34.46N/A
N/A
Alger Capital Appreciation Instl I
HEMCX7.73N/A
N/A
Janus Henderson Emerging Markets C

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with CRSP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+11.92%
CRSP - ABCL
58%
Loosely correlated
+11.58%
NTLA - ABCL
57%
Loosely correlated
+12.74%
BEAM - ABCL
56%
Loosely correlated
+12.59%
VCYT - ABCL
56%
Loosely correlated
+12.88%
ABSI - ABCL
54%
Loosely correlated
+13.66%
More

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
+8.40%
ATAI - CYBN
46%
Loosely correlated
+7.44%
ABCL - CYBN
37%
Loosely correlated
+11.92%
ABSI - CYBN
35%
Loosely correlated
+13.66%
MNMD - CYBN
34%
Loosely correlated
+16.13%
VTGN - CYBN
31%
Poorly correlated
+2.46%
More